Boehringer operating income edges up on Jardiance, animal health

Family-owned Boehringer said in a statement on Tuesday that full-year operating income came in at 4.7 billion euros ($5.16 billion), up from 4.6 billion a year earlier.

The Jardiance group of products, managed in a partnership with Eli Lilly, had 3.9 billion euros in sales, up 25.5%. The diabetes treatment is increasingly used to cut the risk of cardiovascular disease in diabetic patients and also for the treatment of heart failure.

Sales of pulmonary fibrosis drug Ofev rose 21.2% to 2.5 billion euros.

Read also: Eli Lilly, Boehringer Ingelheim gets USFDA nod for Jardiance to treat heart failure regardless of ejection fraction

Growth in animal health products, such as antiparasitics for dogs and cats, was fuelled by more people acquiring a new pet during the pandemic, but Boehringer said it expects to "see a normalization of the market growth trend" in 2022.

For 2022, Boehringer predicted slightly lower group operating income on higher spending on research and development, while revenues are expected to increase slightly.